Man Group’s Filana Therapeutics FLNA Stock Holding History

Man Group’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,988	Closed	-$305K	–	2344
2021 Q4	$305K	Buy	6,988 +3,246	+87%	+$170K	﹤0.01%	1672
2021 Q3	$232K	Sell	3,742 -1,480	-28%	-$124K	﹤0.01%	1716
2021 Q2	$447K	Buy	+5,222	New	+$280K	﹤0.01%	1592

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Man Group's FLNA Position: Q1 2022 in Review

Man Group sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 6,988 shares — an estimated $305K sold.

Man Group first reported a position in FLNA in Q2 2021 and held it in 3 quarters. The position peaked at $447K in Q2 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

Man Group reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
Man Group sold 6,988 Filana Therapeutics shares in Q1 2022, an estimated $305K.
Man Group first reported a position in Filana Therapeutics in Q2 2021 and held it in 3 quarters.
Man Group's Filana Therapeutics position peaked at $447K in Q2 2021.
163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Man Group's 13F filing for Q1 2022, filed 16 May 2022.